Starling Oncology, Inc. Accounts Receivable
Starling Oncology, Inc. (DFPH) had Accounts Receivable of $66.35 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $66.35M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $58.13M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $59.00M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $59.64M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2026-06-30 | $66.35M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $58.13M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $59.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $59.64M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $55.66M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $49.32M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $48.34M 10-K · filed 2026-03-12 |
| 2024-09-30 | $54.50M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $54.02M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $58.76M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $42.36M 10-K · filed 2025-03-26 |
| 2023-09-30 | $48.44M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $46.39M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $45.96M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $39.82M 10-K · filed 2024-03-28 |
| 2022-09-30 | $34.82M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $28.95M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $24.51M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $20.01M 10-K · filed 2023-03-16 |
| 2020-12-31 | $17.15M 10-K · filed 2022-03-11 |